Immunoglobulin gamma-1 heavy chain constant region (IGHG1) forms the scaffold of IgG1, governing complement fixation, Fc-γ-receptor cross-linking and glycosylation-dependent effector programming. Despite divergent triggers, chronic obstructive pulmonary disease, asthma, bronchiectasis and lung cancer converge on three core pathobiological pillars: small-airway occlusion, recurrent exacerbations and deranged mucosal immunity. Whether and how IGHG1 orchestrates this shared trajectory remains enigmatic. Here we synthesise pre-clinical and clinical datasets to chart a unifying IGHG1-centric roadmap that links humoral dysregulation to disease onset , progression and exacerbation across the chronic respiratory spectrum, and outline how precision engineering of the IGHG1–Fc axis may deliver pan-disease immunomodulatory therapeutics.

Xiaoxiao Peng, Daishun Liu. Research Progress on the Role of the Constant Region of Immunoglobulin γ-1 Heavy Chain in Chronic Respiratory Diseases. Frontiers in Medical Science Research (2026), Vol. 8, Issue 1: 72-78. https://doi.org/10.25236/FMSR.2026.080108.

[1] LI H, WANG Y, DUAN H, et al. Immune cell regulatory networks in chronic obstructive pulmonary disease: mechanistic analysis from innate to adaptive immunity[J]. Frontiers in Immunology, 2025, 16: 1651808.

[2] CARLIER F M, DE FAYS C, PILETTE C. Epithelial Barrier Dysfunction in Chronic Respiratory Diseases[J]. Frontiers in Physiology, 2021, 12: 691227.

[3] HU M, WEI S, ZHOU W, et al. Research progress on neonatal Fc receptor and its application[J]. Journal of Zhejiang University (Medical Sciences), 2021, 50(4): 537-544.

[4] OLAFSDOTTIR T A, THORLEIFSSON G, LOPEZ DE LAPUENTE PORTILLA A, et al. Sequence variants influencing the regulation of serum IgG subclass levels[J]. Nature Communications, 2024, 15(1): 8054.

[5] KIM S J, KIM T, CHOI H, et al. Respiratory pathogen and clinical features of hospitalized patients in acute exacerbation of chronic obstructive pulmonary disease after COVID 19 pandemic[J]. Scientific Reports, 2024, 14(1): 10462.

[6] BA TA T, TRAN VIET T, XUAN NGUYEN K, et al. Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations[J]. Advances in Respiratory Medicine, 2022, 90(6): 500-510.

[7] VIDARSSON G, DEKKERS G, RISPENS T. IgG Subclasses and Allotypes: From Structure to Effector Functions[J]. Frontiers in Immunology, 2014, 5: 520.

[8] DEKKERS G, BENTLAGE A E H, STEGMANN T C, et al. Affinity of human IgG subclasses to mouse Fc gamma receptors[J]. mAbs, 2017, 9(5): 767-773.

[9] FEIGE M J, GROSCURTH S, MARCINOWSKI M, et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies[J]. Molecular cell, 2009, 34(5): 569-579.

[10] IZADI A, KARAMI Y, BRATANIS E, et al. The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies[J]. Nature Communications, 2024, 15(1): 3600.

[11] ABDELDAIM D T, SCHINDOWSKI K. Fc-engineered therapeutic antibodies: Recent advances and future directions[J]. Pharmaceutics, 2023, 15(10): 2402.

[12] LU L L, SUSCOVICH T J, FORTUNE S M, et al. Beyond binding: antibody effector functions in infectious diseases[J]. Nature reviews. Immunology, 2018, 18(1): 46-61.

[13] ZHAO J, PENG H, GAO J, et al. Current insights into the expression and functions of tumor-derived immunoglobulins[J]. Cell Death Discovery, 2021, 7(1): 148.

[14] HUANG X, ZHANG S, TANG J, et al. A Self-Propagating c-Met-SOX2 Axis Drives Cancer-Derived IgG Signaling That Promotes Lung Cancer Cell Stemness[J]. Cancer Research, 2023, 83(11): 1866-1882.

[15] WANG P, GAJJAR M R, YU J, et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(30): 18002-18009.

[16] STRUBLE E B, RAWSON J M O, STANTCHEV T, et al. Uses and challenges of antiviral polyclonal and monoclonal antibody therapies[J]. Pharmaceutics, 2023, 15(5): 1538.

[17] MOYO-GWETE T, SCHEEPERS C, MAKHADO Z, et al. Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms[J]. Scientific Reports, 2022, 12(1): 16473.

[18] SUN W, YANG T, SUN F, et al. An IGHG1 variant exhibits polarized prevalence and confers enhanced IgG1 antibody responses against life-threatening organisms[J]. Nature Immunology, 2024, 25(10): 1809-1819.

[19] BAYART C, MULARONI A, HEMMANI N, et al. Tetanus toxin fragment C: Structure, drug discovery research and production[J]. Pharmaceuticals (Basel, Switzerland), 2022, 15(6): 756.

[20] ROWLEY D, THÖNI M, ISLIKER H. Opsonic requirements for bacterial phagocytosis[J]. Nature, 1965, 207(993): 210-211.

[21] SHIELDS R L, NAMENUK A K, HONG K, et al. High resolution mapping of the binding site on human IgG1 for fc gamma RI, fc gamma RII, fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the fc gamma R[J]. The Journal of Biological Chemistry, 2001, 276(9): 6591-6604.

[22] WINKLER E S, GILCHUK P, YU J, et al. Human neutralizing antibodies against SARS-CoV-2 require intact fc effector functions for optimal therapeutic protection[J]. Cell, 2021, 184(7): 1804-1820.e16.

[23] J L, Q M, L C, et al. Transcriptomic and miRNA signatures of ChAdOx1 nCoV-19 vaccine response using machine learning[J/OL]. Life (Basel, Switzerland), 2025, 15(6)[2026-01-12]. 

[24] HU Q, YANG Q, GAO H, et al. Immunoglobulin heavy constant gamma 1 silencing decreases tonicity‐responsive enhancer‐binding protein expression to alleviate diabetic nephropathy[J]. Journal of Diabetes Investigation, 2024, 15(5): 572-583.

[25] Seifert, L., Zahner, G., Meyer-Schwesinger, C. et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat Commun 14, 473 (2023). 

[26] NAVAS A, MOLINA J, AGÜERA M L, et al. Characterization of the C1q-binding ability and the IgG1-4 subclass profile of preformed anti-HLA antibodies by solid-phase assays[J]. Frontiers in Immunology, 2019, 10: 1712.

[27] NEUBAUER A, MAHARRY K, MRÓZEK K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2008, 26(28): 4603-4609.

[28] WANG J, LIN D, PENG H, et al. Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells[J]. Oncotarget, 2014, 5(20): 9727-9743.

[29] SERAPINAS D, NARBEKOVAS A, JUSKEVICIUS J, et al. Systemic inflammation in COPD in relation to smoking status[J]. Multidisciplinary Respiratory Medicine, 2011, 6(4): 214-219.

[30] MA A, WEN L, YIN J, et al. Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2020, 15: 189-200.

[31] HAI C N, BA T T, DUC T B, et al. Serum immunoglobulin levels in group E of chronic obstructive pulmonary disease: Insights for clinical management and immunoglobulin therapy strategies[J]. BMC Pulmonary Medicine, 2024, 24: 381.

[32] FAIZ A, TER HAAR E A M D, HARTMAN J E, et al. Genome-Wide Differential Airway Gene Expression Analysis Identifies Genes Associated with COPD Comorbidities[J]. Lung, 2025, 203(1): 58.

[33] BARANIUK J N, CASADO B, PANNELL L K, et al al. Protein networks in induced sputum from smokers and COPD patients[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2015, 10: 1957-1975.

[34] KIM J H, PARK S, HWANG Y I, et al. Immunoglobulin G Subclass Deficiencies in Adult Patients with Chronic Airway Diseases[J]. Journal of Korean Medical Science, 2016, 31(10): 1560-1565.

[35] SOUTHWORTH T, HIGHAM A, KOLSUM U, et al. The relationship between airway immunoglobulin activity and eosinophils in COPD[J]. Journal of Cellular and Molecular Medicine, 2021, 25(4): 2203-2212.

[36] KOSTINOVA A M, LATYSHEVA E A, AKHMATOVA N K, et al. Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination[J]. Viruses, 2023, 15(10): 2091.

[37] STAPLES K J, TAYLOR S, THOMAS S, et al. Relationships between Mucosal Antibodies, Non-Typeable Haemophilus influenzae (NTHi) Infection and Airway Inflammation in COPD[J]. PloS One, 2016, 11(11): e0167250.

[38] VAZQUEZ M I, CATALAN-DIBENE J, ZLOTNIK A. B cells responses and cytokine production are regulated by their immune microenvironment[J]. Cytokine, 2015, 74(2): 318-326.

[39] PAVIĆ T, DILBER D, KIFER D, et al. N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease[J]. Journal of Translational Medicine, 2018, 16(1): 323.

[40] ANTHONY R M, NIMMERJAHN F, ASHLINE D J, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc[J]. Science (New York, N.Y.), 2008, 320(5874): 373-376.

[41] ZHOU J, TAN Y, WU W, et al. Plasma IgG Glycosylation Profiling Reveals the Biological Features of Early Chronic Obstructive Pulmonary Disease[J]. Journal of Proteome Research, 2025, 24(4): 1804-1816.

[42] KIM J J Y, DENNETT L, OSPINA M B, et al. Effectiveness of immunoglobulin replacement therapy in preventing infections in patients with chronic obstructive pulmonary disease: a systematic review[J]. Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology, 2024, 20: 30.

[43] PAGAN J D, KITAOKA M, ANTHONY R M. Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease[J]. Cell, 2018, 172(3): 564-577.e13.

[44] RIZZO M C, ARRUDA L K, CHAPMAN M D, et al. IgG and IgE antibody responses to dust mite allergens among children with asthma in Brazil[J]. Annals of Allergy, 1993, 71(2): 152-158.

[45] LAU S, ILLI S, PLATTS-MILLS T a. E, et al. Longitudinal study on the relationship between cat allergen and endotoxin exposure, sensitization, cat-specific IgG and development of asthma in childhood--report of the German Multicentre Allergy Study (MAS 90)[J]. Allergy, 2005, 60(6): 766-773.

[46] KITANI S, ITO K, MIYAMOTO T. IgG, IgA, and IgM antibodies to mite in sera and sputa from asthmatic patients[J]. Annals of Allergy, 1985, 55(4): 612-620.

[47] DURHAM S R, LEE T H, CROMWELL O, et al. Immunologic studies in allergen-induced late-phase asthmatic reactions[J]. The Journal of Allergy and Clinical Immunology, 1984, 74(1): 49-60.

[48] OUT T A, VAN DE GRAAF E A, VAN DEN BERG N J, et al. IgG subclasses in bronchoalveolar lavage fluid from patients with asthma[J]. Scandinavian Journal of Immunology, 1991, 33(6): 719-727.

[49] ROBINSON S W. The integration of large biological and clinical datasets towards the understanding of human disease[D/OL]. University of Glasgow, 2020[2026-01-12]. 

[50] HALES B J, MARTIN A C, PEARCE L J, et al. IgE and IgG anti-house dust mite specificities in allergic disease[J]. The Journal of Allergy and Clinical Immunology, 2006, 118(2): 361-367.

[51] OXELIUS V A, CARLSSON A M, AURIVILLIUS M. Alternative G1m, G2m and G3m allotypes of IGHG genes correlate with atopic and nonatopic pathways of immune regulation in children with bronchial asthma[J]. International Archives of Allergy and Immunology, 1998, 115(3): 215-219.

[52] WILLIAMS J W, TJOTA M Y, SPERLING A I. The Contribution of Allergen-Specific IgG to the Development of Th2-Mediated Airway Inflammation[J]. Journal of Allergy, 2012, 2012: 236075.

[53] HILL S, MITCHELL J, BURNETT D, et al. IgG subclasses in the serum and sputum from patients with bronchiectasis[J]. Thorax, 1998, 53(6): 463-468.

[54] KING P T, HUTCHINSON P, HOLMES P W, et al. Assessing immune function in adult bronchiectasis[J]. Clinical and Experimental Immunology, 2006, 144(3): 440-446.

[55] STENLANDER C, LINDAHL H, WAHREN-BORGSTRÖM E, et al. Bronchiectasis, low IgG levels and lack of vaccination are risk factors for covid-19 hospitalization in X-linked agammaglobulinemia - a retrospective multicenter study[J]. Journal of Clinical Immunology, 2025, 45(1): 161.

[56] VENDRELL M, DE GRACIA J, RODRIGO M J, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology[J]. Chest, 2005, 127(1): 197-204.

[57] GRACIA J D, RODRIGO M J, MORELL F, et al. IgG subclass deficiencies associated with bronchiectasis.[J]. American Journal of Respiratory and Critical Care Medicine, 1996, 153(2): 650-655.

[58] NIU Y, LIAN X, LI X, et al. Characteristics of different pathogenic bacterial infections and their effects on prognosis in adult patients with bronchiectasis[J]. Experimental and Therapeutic Medicine, 2024, 28(6): 455.

[59] CABRERA R, ROVIRA-RIBALTA N, MOTOS A, et al. Virulence factors of Pseudomonas aeruginosa and immune response during exacerbations and stable phase in bronchiectasis[J]. Scientific Reports, 2025, 15(1): 6520.

[60] CHEN X, LIU X, XU T, et al. Engineered virus-hunter vaccine overcomes HBV immune tolerance[J/OL]. Gut, 2025[2025-12-16]. 

[61] WANG G, YANG X, ZHU G. Expression and Clinical Significance of Cancer-derived Immunoglobulin G in Non-small Cell Lung Cancer by Bioinformatics and Immunohistochemistry[J]. Chinese Journal of Lung Cancer, 2019, 22(6): 341-348.

[62] WANG Z, GENG Z, SHAO W, et al. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells[J]. Cellular & Molecular Immunology, 2020, 17(11): 1148-1162.

[63] TANG J, ZHANG J, LIU Y, et al. Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling[J]. Cancer Letters, 2018, 430: 148-159.

[64] MA C, WANG Y, ZHANG G, et al. Immunoglobulin G expression and its potential role in primary and metastatic breast cancers[J]. Current Molecular Medicine, 2013, 13(3): 429-437.

[65] LIAO Q, LIU W, LIU Y, et al. Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis[J]. Oncotarget, 2015, 6(37): 40081-40094.

[66] ZHU X, WU L, ZHANG L, et al. Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells[J]. Cellular & Molecular Immunology, 2010, 7(4): 279-286.

[67] CUI X, LIU S, SONG H, et al. Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer[J]. Molecular Cancer, 2025, 24(1): 111.

[68] PRAZANOWSKA K H, HONG J, LIM S B. Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer[J]. Translational Lung Cancer Research, 2023, 12(8): 1816-1821.